Bosentan 62.5 mg Oral Tablet
RxNorm 349253
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 349253 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: bosentan 62.5 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Bosentan 62.5 mg Oral Tablet
(Atom ID: 1541885)
SYPrescribable
Synonym (SY):
Bosentan (as bosentan hydrochloride) 62.5 mg Oral Tablet
(Atom ID: 11443805)
PSNPrescribable
Prescribable Name (PSN):
Bosentan 62.5 mg Oral Tablet
(Atom ID: 6362510)
PTPrescribable
Designated preferred name (PT):
Bosentan 62.5 mg oral tablet
(Atom ID: 12664742)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely bosentan 62.5 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 12665779)
Patient Education
Bosentan
Bosentan is used to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs) in adults and children 3 years of age and older. Bosentan may improve the ability to exercise and slow the worsening of symptoms in patients with PAH. Bosentan is in a class of medications called endothelin receptor antagonists. It works by stopping the action of endothelin, a natural substance that causes blood vessels to narrow and prevents normal blood flow in people who have PAH.
[Learn More]
* Please review the disclaimer below.